Xencor Inc (XNCR)

$7.59 -0.22 (-2.82%)
Market Cap 557.03M
Revenue (ttm) 110.49M
Net Income (ttm) -232.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -210.53%
Debt to Equity Ratio 0.00
Volume 515,200
Avg Vol 706,078
Day's Range N/A - N/A
Shares Out 71.32M
Stochastic %K 51%
Beta 0.89
Analysts Strong Sell
Price Target $29.91

Company Profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab th...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 305 5900
Address:
465 North Halstead Street, Suite 200, Pasadena, United States
dcrown
dcrown Aug. 13 at 12:51 AM
$XNCR finally waking up
0 · Reply
Estimize
Estimize Aug. 12 at 8:00 PM
Wall St is expecting -0.69 EPS for $XNCR Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/xncr?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 1:00 PM
Wedbush updates rating for Xencor ( $XNCR ) to Outperform, target set at 31 → 26.
0 · Reply
Wisenheimer
Wisenheimer Aug. 7 at 2:40 AM
$XNCR royalty revenue down again from $25MM to $18MM after you back out 1x milestone payment
0 · Reply
dcrown
dcrown Aug. 6 at 8:25 PM
$XNCR running tomorrow
0 · Reply
theBigDollarski
theBigDollarski Aug. 6 at 5:02 PM
$XNCR looks good....took a starter position today.
1 · Reply
Klinsmann
Klinsmann Jul. 23 at 5:51 AM
$RKT $XNCR $PEW Midterm holds, no brainer with no need to watch daily
0 · Reply
Klinsmann
Klinsmann Jul. 23 at 5:45 AM
$XNCR in
0 · Reply
Klinsmann
Klinsmann Jul. 21 at 5:27 PM
$XNCR 👀
0 · Reply
Theflash88
Theflash88 Jun. 25 at 2:07 PM
$JANX $XNCR Where did you find that chart.? Excellent
1 · Reply
Latest News on XNCR
Xencor Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 13 days ago

Xencor Reports Second Quarter 2025 Financial Results

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Jul 31, 2025, 4:01 PM EDT - 19 days ago

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 3 months ago

Xencor Reports First Quarter 2025 Financial Results

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Apr 29, 2025, 4:01 PM EDT - 4 months ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Xencor Appoints Todd Simpson to Board of Directors

Mar 13, 2025, 4:01 PM EDT - 5 months ago

Xencor Appoints Todd Simpson to Board of Directors

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:01 AM EST - 6 months ago

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 6 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Xencor to Participate at Upcoming Investor Conferences

Nov 26, 2024, 4:01 PM EST - 9 months ago

Xencor to Participate at Upcoming Investor Conferences

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Nov 22, 2024, 2:00 PM EST - 9 months ago

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Xencor Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 10 months ago

Xencor Reports Third Quarter 2024 Financial Results

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Nov 4, 2024, 7:00 AM EST - 10 months ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Oct 10, 2024, 8:09 AM EDT - 11 months ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Xencor Announces Upcoming Change to Board of Directors

Oct 4, 2024, 8:01 AM EDT - 11 months ago

Xencor Announces Upcoming Change to Board of Directors

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 12, 2024, 8:16 AM EDT - 1 year ago

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Sep 11, 2024, 6:31 AM EDT - 1 year ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Xencor Announces Proposed Public Offering of Common Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Xencor Announces Proposed Public Offering of Common Stock

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Sep 9, 2024, 7:31 AM EDT - 1 year ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Sep 6, 2024, 8:01 AM EDT - 1 year ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Xencor Reports Second Quarter 2024 Financial Results

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Jun 13, 2024, 8:01 AM EDT - 1 year ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Xencor Reports First Quarter 2024 Financial Results

May 9, 2024, 4:09 PM EDT - 1 year ago

Xencor Reports First Quarter 2024 Financial Results

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Xencor to Present at Upcoming Investor Conferences

Feb 28, 2024, 4:01 PM EST - 1 year ago

Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 12:35 AM EST - 1 year ago

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 1 year ago

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Feb 20, 2024, 4:31 PM EST - 1 year ago

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:01 PM EST - 1 year ago

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Jan 2, 2024, 8:01 AM EST - 1 year ago

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

20 favorite small-cap stocks for 2024 among Wall Street analysts

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 4:01 PM EST - 1 year ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 8:29 AM EST - 1 year ago

Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Nov 7, 2023, 4:01 PM EST - 1 year ago

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Xencor Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 4:01 PM EST - 1 year ago

Xencor Reports Third Quarter 2023 Financial Results

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Nov 3, 2023, 12:01 PM EDT - 1 year ago

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Oct 31, 2023, 4:01 PM EDT - 1 year ago

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Xencor: Data In Early 2024 Could Bring Shareholder Value

Oct 27, 2023, 11:56 AM EDT - 1 year ago

Xencor: Data In Early 2024 Could Bring Shareholder Value

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Oct 26, 2023, 8:01 AM EDT - 1 year ago

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Xencor: A Mid-Stage Clinical Company With Falling Losses

Oct 20, 2023, 11:02 PM EDT - 1 year ago

Xencor: A Mid-Stage Clinical Company With Falling Losses

Xencor to Present Multiple Posters at the SITC Annual Meeting

Sep 27, 2023, 9:01 AM EDT - 2 years ago

Xencor to Present Multiple Posters at the SITC Annual Meeting

Xencor Appoints Barbara J. Klencke, M.D.

Sep 19, 2023, 4:01 PM EDT - 2 years ago

Xencor Appoints Barbara J. Klencke, M.D.

Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript

Aug 6, 2023, 3:20 AM EDT - 2 years ago

Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript

Xencor Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 4:01 PM EDT - 2 years ago

Xencor Reports Second Quarter 2023 Financial Results

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

Jul 27, 2023, 8:01 AM EDT - 2 years ago

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

May 30, 2023, 6:01 PM EDT - 2 years ago

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Xencor, Inc. (XNCR) Q1 2023 Earnings Call Transcript

May 8, 2023, 10:25 PM EDT - 2 years ago

Xencor, Inc. (XNCR) Q1 2023 Earnings Call Transcript

Xencor Reports First Quarter 2023 Financial Results

May 8, 2023, 4:01 PM EDT - 2 years ago

Xencor Reports First Quarter 2023 Financial Results

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

May 1, 2023, 4:01 PM EDT - 2 years ago

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Apr 26, 2023, 8:01 AM EDT - 2 years ago

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Apr 17, 2023, 1:31 PM EDT - 2 years ago

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

dcrown
dcrown Aug. 13 at 12:51 AM
$XNCR finally waking up
0 · Reply
Estimize
Estimize Aug. 12 at 8:00 PM
Wall St is expecting -0.69 EPS for $XNCR Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/xncr?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Aug. 7 at 1:00 PM
Wedbush updates rating for Xencor ( $XNCR ) to Outperform, target set at 31 → 26.
0 · Reply
Wisenheimer
Wisenheimer Aug. 7 at 2:40 AM
$XNCR royalty revenue down again from $25MM to $18MM after you back out 1x milestone payment
0 · Reply
dcrown
dcrown Aug. 6 at 8:25 PM
$XNCR running tomorrow
0 · Reply
theBigDollarski
theBigDollarski Aug. 6 at 5:02 PM
$XNCR looks good....took a starter position today.
1 · Reply
Klinsmann
Klinsmann Jul. 23 at 5:51 AM
$RKT $XNCR $PEW Midterm holds, no brainer with no need to watch daily
0 · Reply
Klinsmann
Klinsmann Jul. 23 at 5:45 AM
$XNCR in
0 · Reply
Klinsmann
Klinsmann Jul. 21 at 5:27 PM
$XNCR 👀
0 · Reply
Theflash88
Theflash88 Jun. 25 at 2:07 PM
$JANX $XNCR Where did you find that chart.? Excellent
1 · Reply
Theflash88
Theflash88 Jun. 22 at 7:39 PM
$JANX $XNCR Good info!
0 · Reply
Optionking828
Optionking828 Jun. 21 at 1:14 AM
$JANX Check it out - Wells Fargo Aquisition Potential - We only have 1 Yellow Buyer - Everyone else has two or more except for $XNCR - Going have to research that one.
0 · Reply
Wisenheimer
Wisenheimer Jun. 20 at 4:01 PM
$XNCR sell on news this will hit all time lows soon
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 3 at 2:52 PM
If you missed the +13% 2-day move in $XNCR (so far), you might like this one: $ANIK. Strong buy from all analysts, PT consensus +83% above current price, strong volume, fresh MACD buy signal, rising RSI. Just a FYI...we were just talking about this one in the LIVE ROOM. Oh...and only 14M shares outstanding. I nibbled on a few myself. Holding $XNCR, same setup. Yeah, the chart is ugly...but the R/R is phenomenal.
1 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 3 at 2:43 PM
$XNCR up a bucker from mention last week. A&E bottom playing out. Did you join us? LIVE TRADING ROOM
0 · Reply
Dr_Stoxx
Dr_Stoxx Jun. 2 at 8:21 PM
$XNCR
0 · Reply
RunnerSignals
RunnerSignals May. 30 at 9:03 PM
Friday comeback kings $IVVD $SES $SMTC $GPRO $XNCR turned midday lows into strong closes. great way to finish the week
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 4:43 PM
Barclays has adjusted their stance on Xencor ( $XNCR ), setting the rating to Underweight with a target price of 22 → 6.
0 · Reply
Armonica423
Armonica423 May. 7 at 1:50 AM
$XNCR CYDY
0 · Reply
_www_larval_com_
_www_larval_com_ May. 6 at 7:53 PM
$ENGS -5%[-14%] $IVF -3%[-17%] $ALDX -3%[-22%] $RGC 3%[72%] $XNCR -3%[-18%] most notable movement into the final minutes of trading.
0 · Reply
Quantumup
Quantumup May. 5 at 7:25 PM
BofA reiterated $JANX Buy-$65-Top Pick. $AMGN $XNCR BofA said, " $JANX shares are sliding -6.6% (NBI: - 0.5%) after highlighting plans for phase 1b expansion studies for JANX-007 in mCRPC. Updated PFS data for the 16 patients in the initial readout (see our take on the potential best-in-class responses in our view) demonstrate a lengthening survival tail, especially at the target doses for expansion studies, which contributes to the potential best-in-class profile compared to other clinical programs in development (e.g. Amgen/Xencor's xaluritamig). We continue to see JANX-007 as having the opportunity to expand into earlier lines of therapy, meaningfully adding to the total addressable market and value add. We had a chance to catch up with management and we highlight our takeaways; we maintain Buy and $65 PO and see the share drawback year-to-date as a particularly attractive buying opportunity, with Janux remaining one of our top picks (see our top picks note here)." BofA went on to say:
0 · Reply
JarvisFlow
JarvisFlow Apr. 21 at 3:24 PM
William Blair updates rating for Xencor ( $XNCR ) to Outperform.
0 · Reply